These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21893967)

  • 1. On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome.
    Costa AC
    Dev Neurosci; 2011; 33(5):414-27. PubMed ID: 21893967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.
    Lockrow J; Boger H; Bimonte-Nelson H; Granholm AC
    Behav Brain Res; 2011 Aug; 221(2):610-22. PubMed ID: 20363261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.
    Boada R; Hutaff-Lee C; Schrader A; Weitzenkamp D; Benke TA; Goldson EJ; Costa AC
    Transl Psychiatry; 2012 Jul; 2(7):e141. PubMed ID: 22806212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test.
    Costa AC; Scott-McKean JJ; Stasko MR
    Neuropsychopharmacology; 2008 Jun; 33(7):1624-32. PubMed ID: 17700645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The glutamatergic hypothesis for Down syndrome: the potential use of N-methyl-D-aspartate receptor antagonists to enhance cognition and decelerate neurodegeneration.
    Costa AC
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):16-25. PubMed ID: 24152324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.
    Gardiner KJ
    Drug Des Devel Ther; 2015; 9():103-25. PubMed ID: 25552901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome.
    Ahmed MM; Dhanasekaran AR; Block A; Tong S; Costa AC; Stasko M; Gardiner KJ
    PLoS One; 2015; 10(3):e0119491. PubMed ID: 25793384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GABA
    Block A; Ahmed MM; Rueda N; Hernandez MC; Martinez-Cué C; Gardiner KJ
    Neuroscience; 2018 Feb; 372():192-212. PubMed ID: 29292072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial.
    Costa ACS; Brandão AC; Boada R; Barrionuevo VL; Taylor HG; Roth E; Stasko MR; Johnson MW; Assir FF; Roberto MP; Salmona P; Abreu-Silveira G; Bederman I; Prendergast E; Hüls A; Abrishamcar S; Mustacchi Z; Scheidemantel T; Roizen NJ; Ruedrich S
    Lancet Neurol; 2022 Jan; 21(1):31-41. PubMed ID: 34942135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging and intellectual disability: insights from mouse models of Down syndrome.
    Ruparelia A; Pearn ML; Mobley WC
    Dev Disabil Res Rev; 2013; 18(1):43-50. PubMed ID: 23949828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.
    Faizi M; Bader PL; Tun C; Encarnacion A; Kleschevnikov A; Belichenko P; Saw N; Priestley M; Tsien RW; Mobley WC; Shamloo M
    Neurobiol Dis; 2011 Aug; 43(2):397-413. PubMed ID: 21527343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors.
    Heller HC; Salehi A; Chuluun B; Das D; Lin B; Moghadam S; Garner CC; Colas D
    Neurobiol Learn Mem; 2014 Dec; 116():162-71. PubMed ID: 25463650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine for dementia.
    Areosa Sastre A; McShane R; Sherriff F
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease.
    Emre M; Mecocci P; Stender K
    J Alzheimers Dis; 2008 Jun; 14(2):193-9. PubMed ID: 18560130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.
    Kleschevnikov AM; Belichenko PV; Faizi M; Jacobs LF; Htun K; Shamloo M; Mobley WC
    J Neurosci; 2012 Jul; 32(27):9217-27. PubMed ID: 22764230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome.
    Rueda N; Llorens-Martín M; Flórez J; Valdizán E; Banerjee P; Trejo JL; Martínez-Cué C
    J Alzheimers Dis; 2010; 21(1):277-90. PubMed ID: 20421694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine.
    Scott-McKean JJ; Costa AC
    Learn Mem; 2011 Dec; 18(12):774-8. PubMed ID: 22101180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of pharmacotherapies for cognition in Down syndrome.
    Gardiner KJ
    Trends Pharmacol Sci; 2010 Feb; 31(2):66-73. PubMed ID: 19963286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.